Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC.-Reference-Cited by-同舟云学术

Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC.

Published:2015-05-20 Issue:15_suppl Volume:33 Page:3014-3014
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Antonia Scott Joseph¹,Goldberg Sarah B.²,Balmanoukian Ani Sarkis³,Sanborn Rachel E.⁴,Steele Keith⁵,Narwal Rajesh⁵,Robbins Paul B.⁵,Gu Yu⁵,Karakunnel Joyson Joseph⁵,Rizvi Naiyer A.⁶

Affiliation:

1. Moffitt Cancer Center, Tampa, FL

2. Yale Cancer Center, New Haven, CT

3. The Angeles Clinic and Research Institute, Los Angeles, CA

4. Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR

5. MedImmune, Gaithersburg, MD

6. Columbia University Medical Center, New York, NY

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2015.33.15_suppl.3014

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world effectiveness and safety of recombinant human endostatin plus PD-1 inhibitors and chemotherapy as first-line treatment for EGFR/ALK-negative, advanced or metastatic non-small cell lung cancer;BMC Cancer;2024-08-07

2. Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer;Immunology Letters;2020-05

3. Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment;Frontiers in Pharmacology;2019-10-11

4. Toxicities in Immune Checkpoint Inhibitors;Immune Checkpoint Inhibitors in Cancer;2019

5. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review;Lung Cancer;2017-10